GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x GOLDMAN SACHS ON NEULAND LABS • Reiterate Buy, target price 12,975 from Rs 11,400 • FDA approval for Cobenfy is a key event • FY26 Xanomile estimates to be up 55-60% • CDMO business multiple raised to 40x from 37x

GOLDMAN SACHS ON NEULAND LABS

• Reiterate Buy, target price 12,975 from Rs 11,400

• FDA approval for Cobenfy is a key event

• FY26 Xanomile estimates to be up 55-60%

• CDMO business multiple raised to 40x from 37x GOLDMAN SACHS ON NEULAND LABS

• Reiterate Buy, target price 12,975 from Rs 11,400

• FDA approval for Cobenfy is a key event

• FY26 Xanomile estimates to be up 55-60%

• CDMO business multiple raised to 40x from 37x

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Please follow and like us:
Pin Share

By earn

INTRADAY BUY PIND FOR 2 SEPTEMBER Stocks With Major Volume and News MUTUAL FUND SIP MONEY TRIPPLE IN 10 YEARS FII DATA 18 SEPTEMBER MIDCAP AND SMALL CAP SHARES SELL